Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Dose-escalation and Safety Study of CID-103 Followed by a Randomized, Open-label, Parallel-arm Multi-dose Study Evaluating the Efficacy and Tolerability of CID-103 in Adults With Chronic Immune Thrombocytopenia

NCT07017725 is registered in ClinicalTrials.gov with CASI pharmaceuticals, Inc. as lead sponsor.

NCT NCT07017725
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07017725 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Dose-escalation and Safety Study of CID-103 Followed by a Randomized, Open-label, Parallel-arm Multi-dose Study Evaluating the Efficacy and Tolerability of CID-103 in Adults With Chronic Immune Thrombocytopenia
Lead sponsor
CASI pharmaceuticals, Inc.
Phase
Phase 1/2
Overall status
Recruiting
Start date
January 3, 2025
Completion date
December 30, 2026
Enrollment
75 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

chronic immune thrombocytopenia